Genzyme buys orthopaedic cell therapy firm Verigen
This article was originally published in Clinica
Executive Summary
Genzyme has acquired Verigen, a Leverkusen, Germany-based maker of a new cell therapy system for cartilage repair. It will pay $10m initially, and up to $40m over the next six years, dependent on development and commercial milestones.